HC Wainwright Has Positive Outlook for RAPP FY2027 Earnings

Rapport Therapeutics, Inc. (NASDAQ:RAPP) – Research analysts at HC Wainwright boosted their FY2027 EPS estimates for Rapport Therapeutics in a research note issued to investors on Tuesday, December 9th. HC Wainwright analyst D. Tsao now expects that the company will post earnings of ($3.65) per share for the year, up from their prior estimate of ($3.80). HC Wainwright currently has a “Buy” rating and a $40.00 target price on the stock. The consensus estimate for Rapport Therapeutics’ current full-year earnings is ($3.65) per share. HC Wainwright also issued estimates for Rapport Therapeutics’ FY2028 earnings at ($4.76) EPS and FY2029 earnings at ($3.83) EPS.

Rapport Therapeutics (NASDAQ:RAPP) last released its quarterly earnings results on Thursday, November 6th. The company reported ($0.71) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.77) by $0.06.

RAPP has been the topic of a number of other research reports. Truist Financial assumed coverage on Rapport Therapeutics in a report on Tuesday, September 16th. They issued a “buy” rating and a $44.00 target price on the stock. Wall Street Zen downgraded shares of Rapport Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, December 6th. The Goldman Sachs Group raised shares of Rapport Therapeutics to a “strong-buy” rating in a research report on Friday, September 12th. BTIG Research reiterated a “buy” rating and set a $47.00 target price on shares of Rapport Therapeutics in a research note on Monday, December 8th. Finally, Citizens Jmp increased their price target on shares of Rapport Therapeutics from $77.00 to $80.00 and gave the company a “market outperform” rating in a report on Friday, November 7th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Rapport Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $47.80.

Rapport Therapeutics Stock Performance

Rapport Therapeutics stock opened at $30.27 on Thursday. Rapport Therapeutics has a 52 week low of $6.43 and a 52 week high of $42.27. The firm has a market capitalization of $1.44 billion, a PE ratio of -11.17 and a beta of 1.63. The business’s 50-day simple moving average is $27.02 and its 200-day simple moving average is $20.07.

Institutional Investors Weigh In On Rapport Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. XTX Topco Ltd bought a new position in shares of Rapport Therapeutics during the 1st quarter worth approximately $155,000. Charles Schwab Investment Management Inc. raised its stake in Rapport Therapeutics by 23.8% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 90,968 shares of the company’s stock valued at $912,000 after acquiring an additional 17,459 shares during the period. Deutsche Bank AG lifted its holdings in Rapport Therapeutics by 180.6% during the 1st quarter. Deutsche Bank AG now owns 6,502 shares of the company’s stock valued at $65,000 after purchasing an additional 4,185 shares during the last quarter. Swiss National Bank boosted its position in Rapport Therapeutics by 77.2% during the first quarter. Swiss National Bank now owns 31,900 shares of the company’s stock worth $320,000 after purchasing an additional 13,900 shares during the period. Finally, Nuveen LLC bought a new position in Rapport Therapeutics during the first quarter worth $219,000.

Insiders Place Their Bets

In related news, insider David Bredt sold 8,500 shares of the firm’s stock in a transaction dated Monday, November 17th. The stock was sold at an average price of $25.19, for a total value of $214,115.00. Following the transaction, the insider owned 401,142 shares in the company, valued at $10,104,766.98. This trade represents a 2.07% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Abraham Ceesay sold 40,835 shares of the firm’s stock in a transaction dated Wednesday, September 17th. The stock was sold at an average price of $26.32, for a total value of $1,074,777.20. Following the transaction, the chief executive officer owned 585,412 shares in the company, valued at approximately $15,408,043.84. This trade represents a 6.52% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 115,252 shares of company stock worth $3,001,471 over the last quarter. Corporate insiders own 13.57% of the company’s stock.

About Rapport Therapeutics

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.